Synapse - Paul Hamlin

Results (293)

Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma

Journal Article

Grommes, C.; Pastore, A.; Palaskas, N.; Tang, S. S.; Campos, C.; Schartz, D.; Codega, P.; Nichol, D.; Clark, O.; Hsieh, W. Y.; more...
Cancer Discovery (2017)

Fulltext@MSK | Save

The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma

Journal Article

Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Straus, D. J.; Moskowitz, A. J.; Younes, A.; Matasar, M. J.; more...
Clinical Cancer Research (2017)

Fulltext@MSK | Save

The dual SYK/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase 2 study in patients with relapsed/refractory B cell malignancies

Meeting Abstract

Hamlin, P.; Farber, C.; Fenske, T.; Khatcheressian, J.; Miller, C.; Munoz, J.; Patel, M.; Smith, S.; Stevens, D.; Pandey, A.; more...
Haematologica (2017)

Fulltext@MSK | Save

Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed follicular lymphoma in the rituximab era

Meeting Abstract

Batlevi, C.; Alperovich, A.; Ni, A.; Soumerai, J.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Time from prognosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma

Meeting Abstract

Soumerai, J. D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K. S.; Palomba, M.; Gerecitano, J. F.; Noy, A.; Hamlin, P.; Moskowitz, C. H.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

Meeting Abstract

Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Chen, R.; Constine, L. S.; Courtien, A. I.; Dandapani, S. V.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE

Meeting Abstract

Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Phase I/IB dose escalation and expansion of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma

Meeting Abstract

Batlevi, C.; Hamlin, P.; Matasar, M.; Gerecitano, J.; Drullinsky, P.; Hamilton, A.; Straus, D.; Horwitz, S.; Kumar, A.; Moskowitz, C.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a Phase 2 study in patients with relapsed/refractory B-cell malignancies

Meeting Abstract

Hamlin, P. A.; Farber, C. M.; Fenske, T. S.; Khatcheressian, J. L.; Miller, C. B.; Munoz, J.; Patel, M. R.; Schreeder, M. T.; Smith, S. M.; Stevens, D. A.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Implication of rituximab priming practices

Meeting Abstract

Laudati, C.; Clark, C.; Sumka, J.; Timoney, J.; Hamlin, P.
Oncology Nursing Forum (2017)

Fulltext@MSK | Save